Fig. 5

Validation of DEEPGEN™ in the U.K. Sixteen plasma samples from each cohort of patients originally analyzed with DEEPGEN™ in the respective clinical laboratory (St. George’s and NHS Lothian) was sent to Cleveland, OH to be re-tested with DEEPGEN™ in the UHTL. The frequency and number of drug resistance mutations detected in the U.S. and the respective clinical laboratory in the U.K. are indicated in panels (a) and (b), respectively. Comparisons of the HIV-1 genotypic interpretation and coreceptor tropism determination are depicted in panels (c) and (d). See “Methods” section and figures legends for Figs. 2, 3, and 4 for more details on the study designs